NCT06950177View on ClinicalTrials.gov

Pancoronavirus Vaccine Study in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
COVID-19 Respiratory InfectionSARS CoV 2 InfectionCOVID-19 Vaccine
Interventions
BIOLOGICAL

CoV-RBD-scNP-001 and 3M-052-AF

All subjects will receive the investigational vaccine CoV-RBD-scNP-001 adjuvanted with 3M-052-AF.

Trial Locations (1)

27709

RECRUITING

Duke University Health System, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Duke University

OTHER

NCT06950177 - Pancoronavirus Vaccine Study in Healthy Adults | Biotech Hunter | Biotech Hunter